tamoxifen / p38 Cancer Research Results

Tam, tamoxifen: Click to Expand ⟱
Features:
Tamoxifen is an endocrine anti-hormone drug used to treat breast cancer and other tumours. Tamoxifen is a hormone therapy that treats or prevents hormone receptor-positive breast cancer.

Tamoxifen (TAM; brands include Nolvadex, Soltamox) — an oral selective estrogen receptor modulator (SERM) used primarily for ER+ breast cancer treatment and risk-reduction. Acts as an estrogen receptor antagonist in breast tissue, with partial agonist effects in other tissues.

Primary mechanisms (conceptual rank):
1) ER antagonism in breast → ↓ estrogen-driven transcription/proliferation
2) Prodrug activation to endoxifen (CYP2D6-dependent) → clinical response modulation
3) Cell-cycle arrest + apoptosis downstream of ER blockade (context-dependent)
4) Tumor microenvironment / growth factor cross-talk modulation (e.g., IGF signaling; context-dependent)

Bioavailability / PK relevance: Long half-life; highly protein-bound; hepatic metabolism. Conversion to active metabolite endoxifen depends in part on CYP2D6 activity and interacting drugs. :contentReference[oaicite:0]{index=0}

In-vitro vs oral exposure: Many non-ER “off-target” cytotoxic mechanisms (e.g., lysosomal/mitochondrial disruption) are reported at higher concentrations than typical clinical free-drug exposure; clinically dominant mechanism is ER modulation in ER+ disease. :contentReference[oaicite:1]{index=1}

Clinical evidence status: Established standard therapy and prevention option for ER+ breast cancer; labeling includes serious risks (uterine malignancies and thromboembolic events).

Tamoxifen — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Estrogen Receptor (ERα) transcriptional program ↓ (primary; ER+) ↔ / ↑ (tissue-dependent partial agonism) R/G Antiestrogen growth blockade Core mechanism in ER+ breast cancer; antagonist in breast, partial agonist in endometrium/bone context. :contentReference[oaicite:3]{index=3}
2 Endoxifen activation (CYP2D6-dependent) ↑ efficacy with adequate activation ↔ G Active metabolite exposure Tamoxifen is a prodrug; CYP2D6 affects endoxifen levels and may affect outcomes (drug interactions can matter). :contentReference[oaicite:4]{index=4}
3 Cell cycle (G1 checkpoint; cyclin/CDK) ↓ proliferation (ER+) ↔ G Cytostatic growth arrest Downstream of ER blockade; strongest in hormone-dependent contexts. :contentReference[oaicite:5]{index=5}
4 Apoptosis ↑ (context-dependent) ↔ G Tumor cell death in responsive settings Typically secondary to sustained estrogen deprivation/ER antagonism; variable by tumor biology. :contentReference[oaicite:6]{index=6}
5 PI3K/AKT/mTOR cross-talk ↔ / ↓ (context-dependent) ↔ R/G Growth-factor pathway interplay Common resistance axis in endocrine therapy; not tamoxifen’s primary biochemical target. :contentReference[oaicite:7]{index=7}
6 ROS ↔ / ↑ (high concentration only) ↔ P/R Not a dominant on-target axis Oxidative/mitochondrial effects are reported mainly in vitro at higher concentrations than typical free systemic exposure.
7 NRF2 ↔ ↔ R/G No primary modulation Not a canonical tamoxifen mechanism.
8 HIF-1α ↔ ↔ G No primary role Any hypoxia-axis effects are indirect and model-dependent.
9 Ferroptosis ↔ (not established) ↔ R/G Not canonical Not an established primary mechanism for tamoxifen.
10 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a dominant on-target axis.
11 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Risk + interactions + resistance Key constraints include uterine malignancy and thromboembolic risks (esp. prevention setting), CYP2D6-dependent activation/interaction issues, and endocrine resistance. :contentReference[oaicite:8]{index=8}

TSF legend: P: 0–30 min (receptor binding); R: 30 min–3 hr (acute transcriptional signaling shifts); G: >3 hr (cell-cycle/apoptosis phenotypes)
p38, p38: Click to Expand ⟱
Source:
Type:
P38, or p38 MAPK (p38 mitogen-activated protein kinase), is a protein kinase that plays a significant role in cellular responses to stress, inflammation, and apoptosis (programmed cell death). It is part of the MAPK signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and survival.
It can have both tumor-suppressive and tumor-promoting effects, depending on the type of cancer and the cellular context.

-p38 activation can contribute to tumor progression by influencing inflammatory signaling and cell-cycle regulation.
-Overexpression can correlate with poor prognosis in some studies.
Scientific Papers found: Click to Expand⟱
156- Ralox,  Tam,  GEN,  CUR,    Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ERβ/ESR2↑, TumCG↓, TumCMig↓, FAK↓, p38↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

FAK↓, 1,   TumCMig↓, 1,  

Hormonal & Nuclear Receptors ⓘ

ERβ/ESR2↑, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: p38, p38
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:189  Target#:235  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page